CQS Cayman LP Takes Position in Boston Scientific Corporation (BSX)

Lawrence Kim
January 19, 2018

The rating was maintained by Dundee Securities with "Neutral" on Wednesday, September 21. The company was maintained on Tuesday, October 31 by SunTrust. Approximately 0.9% of the shares of the stock are sold short. SP Angel maintained the stock with "Hold" rating in Wednesday, September 2 report. After $0.70 actual earnings per share reported by California Water Service Group for the previous quarter, Wall Street now forecasts -65.71% negative EPS growth. BSX's profit will be $466.89M for 20.15 P/E if the $0.34 EPS becomes a reality. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 0.70 as current ratio and on the opponent side the debt to equity ratio was 0.75 and long-term debt to equity ratio also remained 0.58. A total of 1.33 million shares exchanged at hands and its average trading volume is standing at 2.14 million shares. About 801,255 shares traded. Webster National Bank N A has invested 0.01% in Boston Scientific Corporation (NYSE:BSX). It has outperformed by 6.14% the S&P500.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Iguana Healthcare Management Llc who had been investing in Boston Scientific Corp for a number of months, seems to be bullish on the $37.71 billion market cap company. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company's shares. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. CAPITAL RESEARCH GLOBAL INVESTORS also announced increased position in Gilead Sciences, Inc. Its up 0.01, from 1.03 in 2017Q2. It improved, as 33 investors sold BSX shares while 166 reduced holdings. Orrstown Finance Serv owns 73 shares for 0% of their portfolio. Cubist Systematic Strategies Ltd holds 0.02% or 13,293 shares in its portfolio. 188,260 are held by S&Co. About 2.30 million shares traded or 330.27% up from the average. Atalanta Sosnoff Cap Limited Liability Co holds 1.22 million shares. State Treasurer State Of Michigan has 0.1% invested in Boston Scientific Corporation (NYSE:BSX) for 416,396 shares. Advsrs Limited Liability holds 34,800 shares or 0.44% of its portfolio.

In other news, SVP David A. Pierce sold 10,232 shares of Boston Scientific Corporation stock in a transaction on Monday, January 9th. Sei Invests reported 264 shares. Swiss Natl Bank owns 0.19% invested in Boston Scientific Corporation (NYSE:BSX) for 5.66 million shares. Tokio Marine Asset Mngmt Ltd, Japan-based fund reported 11,909 shares. $1.56M worth of Boston Scientific Corporation (NYSE:BSX) was sold by Nanavaty Maulik on Wednesday, August 30.

Athena Capital Advisors Llc, which manages about $5.10B and $388.33 million US Long portfolio, decreased its stake in Powershs Db Multi Sect Comm (DBA) by 44,527 shares to 122,921 shares, valued at $2.33M in 2017Q3, according to the filing.

Shares of Boston Scientific (NYSE:BSX) opened at $27.25 on Thursday. Phalen Michael P. had sold 15,500 shares worth $445,137. DnB Asset Management AS now owns 151,150 shares of the medical equipment provider's stock valued at $3,747,000 after purchasing an additional 17,500 shares in the last quarter. Therefore 79% are positive.

Currently, 0.10% of Boston Scientific Corporation (NYSE:BSX) are owned by insiders with 94.12% six-month change in the insider ownership. The stock of Boston Scientific Corporation (NYSE:BSX) has "Buy" rating given on Tuesday, December 12 by BMO Capital Markets. The firm has "Buy" rating given on Wednesday, November 29 by Cowen & Co. Boston Scientific has a twelve month low of $23.29 and a twelve month high of $29.93. BMO Capital Markets maintained the stock with "Buy" rating in Tuesday, December 12 report. The stock of Boston Scientific Corporation (NYSE:BSX) earned "Buy" rating by Needham on Friday, February 3. "On Friday, October 16 the stock rating was downgraded by RBC Capital Markets to ". The stock has "Strong Buy" rating by Raymond James on Monday, October 5. The rating was upgraded by BTIG Research on Thursday, November 30 to "Buy".

Investors sentiment decreased to 0.77 in Q3 2017. It fall, as 16 investors sold STRP shares while 24 reduced holdings. 121 funds opened positions while 404 raised stakes. Great West Life Assurance Can holds 0% of its portfolio in Amur Minerals Corporation (LON:AMC) for 5,558 shares. Aldebaran Financial Inc., a Tennessee-based fund reported 22,240 shares. Tiaa Cref Inv accumulated 146,681 shares. Price T Rowe Associate Md, a Maryland-based fund reported 2.41M shares. Engineers Gate Manager Lp accumulated 0.01% or 10,000 shares. Moreover, Ww Asset Mngmt has 0.13% invested in Boston Scientific Corporation (NYSE:BSX). Credit Suisse Ag owns 234,042 shares. BSX's insider trading patterns have some implications for where the stock might be headed. About 631,389 shares traded. bluebird bio, Inc. Amur Minerals Corporation (LON:AMC) has 0.00% since January 15, 2017 and is. It has underperformed by 0.05% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article